Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03721510 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03721510 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 19 participants.
The verdict
NCT03721510, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a Phase 1/2a open label study to evaluate the safety, tolerability, pharmacokinetics and anti-viral activity of PGT121, VRC07-523LS and PGDM1400 for HIV prevention and therapy.
Interventions
- BIOLOGICAL PGT121 + VRC07-523LS
- BIOLOGICAL PGT121 + VRC07-523LS + PGDM1400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2022-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03721510
The ClinicalTrials.gov registry entry for NCT03721510 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PGT121 + VRC07-523LS is the first listed.
NCT03721510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03721510 about?
NCT03721510 is a clinical study titled "A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults". This is a Phase 1/2a open label study to evaluate the safety, tolerability, pharmacokinetics and anti-viral activity of PGT121, VRC07-523LS and PGDM1400 for HIV prevention and therapy.
What is the current status of trial NCT03721510?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-12-03. Estimated completion is 2022-05-02.
What interventions are being tested in trial NCT03721510?
The interventions under investigation include: PGT121 + VRC07-523LS (BIOLOGICAL), PGT121 + VRC07-523LS + PGDM1400 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03721510?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.